These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35266010)

  • 1. Potential mechanisms of osteoprotegerin-induced damage to osteoclast adhesion structures via P2X7R-mediated MAPK signaling.
    Ma Y; Shi X; Zhao H; Song R; Zou H; Zhu J; Liu Z
    Int J Mol Med; 2022 May; 49(5):. PubMed ID: 35266010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of P2X7R- mediated Ca
    Ma Y; Ran D; Zhao H; Shi X; Song R; Zou H; Liu Z
    Life Sci; 2022 Mar; 293():120337. PubMed ID: 35074408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of P2X7R-mediated Ca
    Ma Y; Zhao H; Chile C; Wang C; Zheng J; Song R; Zou H; Gu J; YanYuan ; Bian J; Liu Z
    Exp Cell Res; 2019 Oct; 383(2):111555. PubMed ID: 31415763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin induces podosome disassembly in osteoclasts through calcium, ERK, and p38 MAPK signaling pathways.
    Zhao H; Liu X; Zou H; Dai N; Yao L; Gao Q; Liu W; Gu J; Yuan Y; Bian J; Liu Z
    Cytokine; 2015 Feb; 71(2):199-206. PubMed ID: 25461399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of osteoclast bone resorption activity through osteoprotegerin-induced damage of the sealing zone.
    Song R; Gu J; Liu X; Zhu J; Wang Q; Gao Q; Zhang J; Cheng L; Tong X; Qi X; Yuan Y; Liu Z
    Int J Mol Med; 2014 Sep; 34(3):856-62. PubMed ID: 25017214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK.
    Theoleyre S; Wittrant Y; Couillaud S; Vusio P; Berreur M; Dunstan C; Blanchard F; Rédini F; Heymann D
    Biochim Biophys Acta; 2004 Feb; 1644(1):1-7. PubMed ID: 14741739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
    J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of the mitogen‑activated protein kinase signaling pathway in osteoprotegerin‑induced inhibition of osteoclast differentiation and maturation.
    Fu Y; Gu J; Wang Y; Yuan Y; Liu X; Bian J; Liu Z
    Mol Med Rep; 2015 Nov; 12(5):6939-45. PubMed ID: 26329402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
    Kwan Tat S; Pelletier JP; Lajeunesse D; Fahmi H; Lavigne M; Martel-Pelletier J
    Clin Exp Rheumatol; 2008; 26(2):295-304. PubMed ID: 18565252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
    Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
    Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of mTORC1 in B Lymphocytes Promotes Osteoclast Formation via Regulation of β-Catenin and RANKL/OPG.
    Xu S; Zhang Y; Liu B; Li K; Huang B; Yan B; Zhang Z; Liang K; Jia C; Lin J; Zeng C; Cai D; Jin D; Jiang Y; Bai X
    J Bone Miner Res; 2016 Jul; 31(7):1320-33. PubMed ID: 26825871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption.
    Tao H; Okamoto M; Nishikawa M; Yoshikawa H; Myoui A
    PLoS One; 2011; 6(8):e23199. PubMed ID: 21886782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels.
    Kondo T; Kitazawa R; Yamaguchi A; Kitazawa S
    J Cell Biochem; 2008 Jan; 103(1):335-45. PubMed ID: 17516544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiosteoclastic bone resorption activity of osteoprotegerin via enhanced AKT/mTOR/ULK1-mediated autophagic pathway.
    Zhao H; Sun Z; Ma Y; Song R; Yuan Y; Bian J; Gu J; Liu Z
    J Cell Physiol; 2020 Mar; 235(3):3002-3012. PubMed ID: 31535378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T; Feng X
    Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG.
    Aoyama E; Kubota S; Khattab HM; Nishida T; Takigawa M
    Bone; 2015 Apr; 73():242-8. PubMed ID: 25554597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.